AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q1 FY20 results · Apr–Jun 2019
AstraZeneca Pharma India reported revenue from operations of ₹204.56 crore (up 26.7% from Q1 FY19) and net profit of ₹21.52 crore (up 236.5% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a standalone basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 204.56 | 161.44 | +26.7% | 190.30 | +7.5% |
| Other income | 2.99 | 3.42 | −12.7% | 6.01 | −50.3% |
| Total income | 207.55 | 164.86 | +25.9% | 196.31 | +5.7% |
| Profit before tax | 33.63 | 9.15 | +267.5% | 8.47 | +296.9% |
| Net profit for the period | 21.52 | 6.39 | +236.5% | 9.82 | +119.0% |
| EPS, basic (₹) | 8.61 | 2.56 | +236.6% | 3.93 | +119.0% |
| Net margin (%) | 10.5 | 4.0 | 5.2 |
Standalone
- Filed with BSE
- 08 Aug 2019, 13:47 IST
- Board meeting
- 07 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE